Lichen planus pemphigoides: A unique form of bullous and lichenoid eruptions secondary to nivolumab

Department

Dermatology

Document Type

Article

Publication Title

Dermatologic Therapy

Abstract

The widespread use of PD-1 inhibitors to treat various solid tumors has brought certain challenges for the clinician, including immune-related adverse events (irAEs). Cutaneous toxicities are among the most observed irAEs. Bullous and lichenoid dermatoses following PD-1 inhibitor therapy have been described. Here we report a novel case of lichen planus pemphigoides, featuring characteristics of both bullous pemphigoid and lichen planus, in a patient treated with nivolumab for renal cell carcinoma. We subsequently review all three cutaneous conditions which may arise in the context of PD-1 inhibitor therapy.

First Page

e15432

DOI

10.1111/dth.15432

Volume

35

Issue

5

Publication Date

5-1-2022

Medical Subject Headings

Carcinoma, Renal Cell (drug therapy); Female; Humans; Immune Checkpoint Inhibitors; Kidney Neoplasms; Lichen Planus (chemically induced, diagnosis, drug therapy); Lichenoid Eruptions (chemically induced, diagnosis); Male; Nivolumab (adverse effects)

PubMed ID

35266258

Link to Full Text

Share

COinS